Clinical data for patients with acute myeloid leukemia
Patient no. . | Age, y/sex . | Diagnosis . | Cytogenetics . | Source . | Blasts, % . | CD34+, %* . |
|---|---|---|---|---|---|---|
| 1 | 62/F | AML, refractory | 46, XX | BM | 67 | 68 |
| 2 | 40/F | AML, relapse | 52, XX, +X, +8, del(11)(q23), +13, +19, +20, +21 | PB | 90 | 96 |
| 3 | 22/M | AML, new | 46, XY, inv(16)(p13q22) | BM | 81 | 93 |
| 4 | 65/F | AML, refractory | 45, XX, -7 | BM | 62 | 79 |
| 5 | 78/F | AML, relapse | 45, X, -X | BM | 60 | 92 |
| 6 | 25/M | AML, therapy-related | 46,XY,t(2;11)(q31;p15) | PB | 92 | 44 |
| 7 | 25/F | AML, relapse | 46, XX | PB | 60 | 77 |
| 8 | 23/F | AML, refractory | 45, XX, inv(3)(q21q26), -7 | BM | 70 | 65 |
| 9 | 79/M | RAEB/AML | 46, XY, t(2;12)(q31;p13) | PB | 62 | 76 |
| 10 | 39/M | AML, new | 46, XY, +21 | BM | 74 | 29 |
| 11 | 25/F | AML, new | 46, XX, t(8;21)(q22;q22) | BM | 60 | 23 |
| 12 | 61/F | AML, new | 46, XX, t(9;11)(p22;q23) | BM | 85 | 4 |
| 13 | 47/F | AML, relapse | 46, XX, t(1;16)(p33;p13) | BM | 74 | 54 |
| 14 | 57/M | AML, relapse | 46, XY | BM | 99 | 11 |
| 15 | 59/F | AML, new | 46, XX | BM | 69 | 71 |
| 16 | 37/F | AML, relapse | 44, XX, t(3;3)(q21;q26), -7, -10 | PB | 87 | 92 |
| 17 | 59/F | AML, new | 46, XX | PB | 91 | 1 |
| 18 | 44/M | AML, relapse | 46, XY | BM | 93 | 98 |
Patient no. . | Age, y/sex . | Diagnosis . | Cytogenetics . | Source . | Blasts, % . | CD34+, %* . |
|---|---|---|---|---|---|---|
| 1 | 62/F | AML, refractory | 46, XX | BM | 67 | 68 |
| 2 | 40/F | AML, relapse | 52, XX, +X, +8, del(11)(q23), +13, +19, +20, +21 | PB | 90 | 96 |
| 3 | 22/M | AML, new | 46, XY, inv(16)(p13q22) | BM | 81 | 93 |
| 4 | 65/F | AML, refractory | 45, XX, -7 | BM | 62 | 79 |
| 5 | 78/F | AML, relapse | 45, X, -X | BM | 60 | 92 |
| 6 | 25/M | AML, therapy-related | 46,XY,t(2;11)(q31;p15) | PB | 92 | 44 |
| 7 | 25/F | AML, relapse | 46, XX | PB | 60 | 77 |
| 8 | 23/F | AML, refractory | 45, XX, inv(3)(q21q26), -7 | BM | 70 | 65 |
| 9 | 79/M | RAEB/AML | 46, XY, t(2;12)(q31;p13) | PB | 62 | 76 |
| 10 | 39/M | AML, new | 46, XY, +21 | BM | 74 | 29 |
| 11 | 25/F | AML, new | 46, XX, t(8;21)(q22;q22) | BM | 60 | 23 |
| 12 | 61/F | AML, new | 46, XX, t(9;11)(p22;q23) | BM | 85 | 4 |
| 13 | 47/F | AML, relapse | 46, XX, t(1;16)(p33;p13) | BM | 74 | 54 |
| 14 | 57/M | AML, relapse | 46, XY | BM | 99 | 11 |
| 15 | 59/F | AML, new | 46, XX | BM | 69 | 71 |
| 16 | 37/F | AML, relapse | 44, XX, t(3;3)(q21;q26), -7, -10 | PB | 87 | 92 |
| 17 | 59/F | AML, new | 46, XX | PB | 91 | 1 |
| 18 | 44/M | AML, relapse | 46, XY | BM | 93 | 98 |
AML indicates acute myeloid leukemia; RAEB, refractory anemia with excess blasts; PB, peripheral blood; BM, bone marrow.
The percentage of CD34+ cells was determined by flow cytometry in isolated bone marrow mononuclear cells or peripheral blood mononuclear cells.